Blood cancers refer to a collection of hematological cancers characterized by an abnormal production and regulation of blood cells in the body. As opposed to other tumors that usually arise from organs and tissues, these cancers spread in the bloodstream and bone marrow and are systemic. Knowledge on blood cancer is important because diagnosis and treatment at an early stage may positively affect a patient’s survival rate. With the development of targeted therapies like Acalabrutinib, Enasidenib, and Ibrutinib, treatment becomes easy due to their effectiveness.
What Are Blood Cancers?
Blood cancers are malignancies that develop from the malfunctioning and proliferation of blood-producing cells. Blood cancers affect the normal formation of blood cells causing the weakening of the immune system, decreased oxygen transportation, and clotting disorders. Typically, the disease starts from the bone marrow due to genetic alterations of immature or malfunctioning cells which start to multiply and replace normal cells.
What Are the Types of Blood Cancer?
The types of blood cancers are generally classified depending on their cause and cells involved as follows:
1. Leukemia: This is caused by an increase number of abnormal white blood cells in the blood and bone marrow, and it may be either acute or chronic.
2. Lymphoma: It is caused by lymphocytes, which affect the lymph nodes and other lymphatic structures in the body.
3. Multiple Myeloma: It occurs due to the growth of malignant plasma cells resulting in defective antibody formation and bone diseases.
What Causes Blood Cancer?
Blood cancer development results from genetic and molecular defects, which affect cell regulation. Although the specific causes may sometimes remain unknown, the following have been established as some of the causes:
- Genetic mutation acquired by hematopoietic stem cells.
- Ionizing radiation or chemical exposure.
- Underlying immune system dysregulation.
- Previous treatment using chemotherapy or radiation therapy.
- Genetic predisposition in some individuals.
These factors combine to lead to malignant cell transformation.
What Are the Symptoms of Blood Cancer?
The manifestation is highly variable, but the following are some symptoms associated with the impairment of the function of the blood cells:
- Fatigue caused by anemia.
- Recurrent or severe infections due to immune system suppression.
- Bruising easily or bleeding because of lack of platelets.
- Unexpected weight loss and night sweats.
- Bone pain due to bone marrow involvement.
The symptoms mentioned above are often progressive and slow in developing; therefore, clinical attentiveness is crucial.
How Are Blood Cancers Diagnosed?
A Blood Cancer diagnosis must be made through an organized and scientific process to verify the existence of the disease and classify it into types:
1. CBC (complete blood count): It helps in detecting any changes in blood cells.
2. Bone marrow biopsy: The methodsupplies conclusive evidence regarding the nature of cells.
3. Molecular and cytogenetics tests: It helps to detect the mutation so that targeted therapy can be administered.
4. Imaging techniques: Are used to assess the involvement of organs in the disease process.
How Has Blood Cancer Treatment Evolved?
There have been remarkable changes in the treatment options for blood cancers. The classical treatment option through chemotherapy has since been complemented with targeted therapy and immunomodulatory drugs. Current Evolution of blood Cancer include:
- Targeting specific pathways associated with cancer.
- Less toxic than traditional chemotherapy.
- Disease control in the long term.
Such changes are an indication of how treatments have been personalized over time.
What Medicines Are Used for Blood Cancer?
There are various treatments for blood cancer, which include advanced forms of medication for the proper management of cancer cells, such as:
1. Acalabrutinib
Brand Name: CALQUENCE 100mg, ACALUXEN 100mg
Benefits:
- Acalabrutinib blocks selectively the tyrosine kinase enzyme (BTK), which plays a crucial role in developing B-cell cancers.
- It has been found effective for specific types of leukemia and lymphoma and works to control the progress of the disease.
- It provides an alternative form of treatment that is better tolerated by the patients compared to conventional forms of treatment.
Possible side effects caused by the medicine
- Headache
- Fatigue
- Diarrhea
- Increased risk of infections
2. Enasidenib
Brand: IDHIFA 50mg, ENASINIB 50mg
Benefits
- Enasidenib targets the mutations in IDH2, a process that leads to the uncontrolled development of cells in some types of leukemia. In this regard, by targeting the mutation, the medicine is helpful in managing the development of the disease from a molecular perspective.
- Helps the immature cancerous cells mature into healthy blood cells thus ensuring efficient functioning of the blood cells.
- Acts as a targeted therapy in treating leukemia since it acts based on the specific mutation in the cell.
Possible side effects caused by the medicine
- Nausea
- Decreased appetite
- Elevated bilirubin levels
- Fatigue
3. Ibrutinib
Brand: IMBRUVICA 140mg, IBRUXEN 140mg
Benefits:
- Ibrutinib blocks Bruton’s tyrosine kinase (BTK) pathway, which is an essential pathway involved in the proliferation and survival of cancer cells. Through blocking the pathway, it plays a role in hindering the progression of malignant cells.
- It is commonly used in treating chronic lymphocytic leukemia (CLL), as well as other conditions involving B-cell cancers, thereby being a critical targeted therapy in the management of blood cancer.
- It should be taken orally, and thus provides the benefit of easy administration for sustained control of the disease condition.
Possible side effects caused by the medicine
- Diarrhea
- Hypertension
- Bleeding risk
- Musculoskeletal pain
What Is Precision Medicine in Blood Cancer Care?
Precision medicine has revolutionized oncology through treatments based on the genetics and molecules of the disease. This involves moving away from using a one-size-fits-all approach to treatment and instead using biomarkers to identify the appropriate treatment for the patient. This ensures that there is an improvement in the effectiveness of treatment, reduces side effects and also enables therapy changes to be made depending on how the disease progresses.
Conclusion
Even though blood cancers can be rather complicated to treat, it is getting easier to manage patients with these conditions due to recent developments in targeted medicine and molecular diagnostics. A systematic way of diagnosis and personalized treatment can help improve the outcome. Further progress in precision medicine will contribute even more to better results.
FAQs
1. Why is genetic testing necessary for blood cancer?
Genetic testing will help determine any mutations that may be used to determine the most appropriate targeted treatment therapy.
2. Are all patients under the same treatment?
No, treatment depends on the cancer and genetic factors.
References
- Adeyemi, S. A., Ngema, L. M., & Choonara, Y. E. (2025). Advances in targeted therapies and emerging strategies for blood cancer treatment. RSC Pharmaceutics, 2(5), 950-961. Https://www.researchgate.net/publication/393234676_Advances_in_targeted_therapies_and_emerging_strategies_for_blood_cancer_treatment
- Saha, S., Ghosh, S., Ghosh, S., & Nandi, S. (2024). A Comprehensive Review on Unravelling the Complexity of Blood Cancer. blood, 6, 7. Https://globalresearchonline.net/ijpsrr/v84-3/20.pdf
- Abbas, H. A., & Wierda, W. G. (2021). Acalabrutinib: a selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies. Frontiers in oncology, 11, 668162. Https://pubmed.ncbi.nlm.nih.gov/34055635/
- De Botton, S., Montesinos, P., Schuh, A. C., Papayannidis, C., Vyas, P., Wei, A. H., … & DiNardo, C. D. (2023). Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. Blood, 141(2), 156-167. Https://pubmed.ncbi.nlm.nih.gov/35714312/
- Deeks, E. D. (2017). Ibrutinib: a review in chronic lymphocytic leukaemia. Drugs, 77(2), 225-236. Https://pubmed.ncbi.nlm.nih.gov/28105602/
